The management of CKD: A look into the future

Kidney International

Volumn 72, Issue 11, 2007, Pages 1316-1323

  Khwaja, A ^a,c   El Kossi, M ^a   Floege, J ^b   El Nahas, M ^a  

^a Sheffield Kidney Institute ^*  (United Kingdom)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cell signaling; Cell survival; Chronic kidney disease; Cytokines; Renal fibrosis

Indexed keywords

CELL ACTIVITY; CELL LOSS; CELL PROLIFERATION; CELL TRANSFORMATION; CHRONIC KIDNEY DISEASE; EXTRACELLULAR MATRIX; HUMAN; KIDNEY FIBROSIS; NEPHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; REGENERATIVE ABILITY; REVIEW;

EID: 36248929970     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002489     Document Type: Review

References (92)

1. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
2. Lameire N, Jager K, Van Biesen W et al. Chronic kidney disease: a European perspective. Kidney Int Suppl 2005; 99: S30-S38.
3. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
4. Wharram BL, Goyal M, Wiggins JE et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
5. Bohle A, Wehrmann M, Bogenschutz O et al. The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 1992; 188: 908-924.
6. Rodemann HP, Muller GA. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991; 17: 684-686.
7. Remuzzi G, Perico N, Macia M et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 99: S57-S65.
8. Thomas GL, Yang B, Wagner BE et al. Cellular apoptosis and proliferation in experimental renal fibrosis. Nephrol Dial Transplant 1998; 13: 2216-2226.
9. Hugo C, Shankland SJ, Bowen-Pope DF et al. Extraglomerular origin of the mesangial cell after injury. A new role of the juxtaglomerular apparatus. J Clin Invest 1997; 100: 786-794.
10. Sakai N, Iseki K, Suzuki S et al. Uninephrectomy induces progressive glomerulosclerosis and apoptosis in anti-Thy1 glomerulonephritis. Pathol Int 2005; 55: 19-26.
11. Wolthuis A, van Goor H, Weening JJ et al. Pathobiology of focal sclerosis. Curr Opin Nephrol Hypertens 1993; 2: 458-464.
12. Kriz W. The pathogenesis of 'classic' focal segmental glomerulosclerosis-lessons from rat models. Nephrol Dial Transplant 2003; 18(Suppl 6): vi39-vi44.
13. Yang B, Johnson TS, Haylor JL et al. Effects of caspase inhibition on the progression of experimental glomerulonephritis. Kidney Int 2003; 63: 2050-2064.
14. Yang B, Johnson TS, Thomas GL et al. A shift in the Bax/Bcl-2 balance may activate caspase-3 and modulate apoptosis in experimental glomerulonephritis. Kidney Int 2002; 62: 1301-1313.
15. Hughes J, Savill JS. Apoptosis in glomerulonephritis. Curr Opin Nephrol Hypertens 2005; 14: 389-395.
16. Badid C, Vincent M, Fouque D et al. Myofibroblast: a prognostic marker and target cell in progressive renal disease. Ren Fail 2001; 23: 543-549.
17. Floege J, Eitner F, Alpers C. A new look at platelet-derived growth factor and renal disease. J Am Soc Nephrol 2007 (in press).
18. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
19. Berman E, Nicolaides M, Maki RG et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013.
20. Francois H, Placier S, Flamant M et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 2004; 18: 926-928.
21. Lautrette A, Li S, Alili R et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11: 867-874.
22. Floege J, Eng E, Young BA et al. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int Suppl 1993; 39: S47-S54.
23. Kanda S, Nomata K, Saha PK et al. Growth factor regulation of the renal cortical tubular cells by epidermal growth factor, insulin-like growth factor-I, acidic and basic fibroblast growth factor, and transforming growth factor-beta in serum free culture. Cell Biol Int Rep 1989; 13: 687-699.
24. Ballermann BJ. Regulation of bovine glomerular endothelial cell growth in vitro. Am J Physiol 1989; 256: C182-C189.
25. Takeuchi A, Yoshizawa N, Yamamoto M et al. Basic fibroblast growth factor promotes proliferation of rat glomerular visceral epithelial cells in vitro. Am J Pathol 1992; 141: 107-116.
26. Strutz F, Zeisberg M, Hemmerlein B et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 2000; 57: 1521-1538.
27. Strutz F, Zeisberg M, Ziyadeh FN et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002; 61: 1714-1728.
28. Floege J, Kriz W, Schulze M et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 1995; 96: 2809-2819.
29. Floege J, Burg M, Hugo C et al. Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 1998; 9: 792-801.
30. Ziche M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets 2004; 5: 485-493.
31. Gherardi D, D'Agati V, Chu TH et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004; 15: 1212-1222.
32. Pippin JW, Qu Q, Meijer L et al. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997; 100: 2512-2520.
33. Bukanov NO, Smith LA, Klinger KW et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006; 444: 949-952.
34. Phanish MK, Wahab NA, Hendry BM et al. TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol 2005; 100: e156-e165.
35. Bokemeyer D, Panek D, Kramer HJ et al. In vivo identification of the mitogen-activated protein kinase cascade as a central pathogenic pathway in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2002; 13: 1473-1480.
36. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
37. Jo SK, Cho WY, Sung SA et al. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 2005; 67: 458-466.
38. Omori S, Hida M, Fujita H et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006; 17: 1604-1614.
39. Christensen M, Su AW, Snyder RW et al. Simvastatin protection against acute immune-mediated glomerulonephritis in mice. Kidney Int 2006; 69: 457-463.
40. Khwaja A, O'Connolly J, Hendry BM. Prenylation inhibitors in renal disease. Lancet 2000; 355: 741-744.
41. Hayashi K, Wakino S, Kanda T et al. Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J Pharmacol Sci 2006; 100: 29-33.
42. Fu P, Liu F, Su S et al. Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol 2006; 17: 3105-3114.
43. Neilson EG. Mechanisms of disease: fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2006; 2: 101-108.
44. Tumbarello DA, Turner CE. Hic-5 contributes to epithelial-mesenchymal transformation through a RhoA/ROCK-dependent pathway. J Cell Physiol 2007; 211: 736-747.
45. Yu L, Border WA, Anderson I et al. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004; 66: 1774-1784.
46. Juarez P, Vilchis-Landeros MM, Ponce-Coria J et al. Soluble betaglycan reduces renal damage progression in db/db mice. Am J Physiol Renal Physiol 2007; 292: F321-F329.
47. Akagi Y, Isaka Y, Arai M et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148-155.
48. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020.
49. Moon JA, Kim HT, Cho IS et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006; 70: 1234-1243.
50. Dai C, Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 2004; 15: 1402-1412.
51. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2003; 284: F349-F357.
52. Mizuno S, Nakamura T. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 2004; 286: F134-F143.
53. Azuma H, Takahara S, Matsumoto K et al. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 2001; 12: 1280-1292.
54. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968.
55. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl 2003; 87: S105-S112.
56. Davies MR, Lund RJ, Mathew S et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16: 917-928.
57. Gonzalez EA, Lund RJ, Martin KJ et al. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int 2002; 61: 1322-1331.
58. Yanagita M. Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int 2006; 70: 989-993.
59. Yanagita M, Okuda T, Endo S et al. Uterine sensitization- associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest 2006; 116: 70-79.
60. Lin J, Patel SR, Cheng X et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 2005; 11: 387-393.
61. Lan HY, Mu W, Tomita N et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003; 14: 1535-1548.
62. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 2005; 289: F227-F234.
63. Kitagawa K, Wada T, Furuichi K et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004; 165: 237-246.
64. Li P, Garcia GE, Xia Y et al. Blocking of monocyte chemoattractant protein-1 during tubulointerstitial nephritis resulted in delayed neutrophil clearance. Am J Pathol 2005; 167: 637-649.
65. Shimizu H, Maruyama S, Yuzawa Y et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003; 14: 1496-1505.
66. Lloyd CM, Minto AW, Dorf ME et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185: 1371-1380.
67. Vielhauer V, Berning E, Eis V et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004; 66: 2264-2278.
68. Anders HJ, Belemezova E, Eis V et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004; 15: 1504-1513.
69. Anders HJ, Vielhauer V, Frink M et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002; 109: 251-259.
70. Furuichi K, Gao JL, Murphy PM. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 2006; 169: 372-387.
71. Kelly DJ, Chanty A, Gow RM et al. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005; 16: 1654-1660.
72. Kelly DJ, Zhang Y, Hepper C et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52: 512-518.
73. Tuttle KR, Bakris GL, Toto RD et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28: 2686-2690.
74. Sato M, Shegogue D, Gore EA et al. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest Dermatol 2002; 118: 704-711.
75. Chin BY, Mohsenin A, Li SX et al. Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway. Am J Physiol Renal Physiol 2001; 280: F495-F504.
76. Stambe C, Atkins RC, Tesch GH et al. The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 2004; 15: 370-379.
77. Li J, Campanale NV, Liang RJ et al. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006; 169: 1527-1540.
78. Matsuo S, Morita Y, Mizuno M et al. Proteinuria and damage to tubular cells - is complement a culprit? Nephrol Dial Transplant 1998; 13: 2723-2726.
79. Bao L, Wang Y, Chang A et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 2007; 18: 811-822.
80. He C, Imai M, Song H et al. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol 2005; 174: 5750-5757.
81. Boor P, Konieczny A, Villa L et al. Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol 2007; 18: 1508-1515.
82. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
83. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
84. Masuda Y, Shimizu A, Mori T et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001; 159: 599-608.
85. de Vriese AS, Tilton RG, Elger M et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
86. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
87. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-beta as the major mediator. J Am Soc Nephrol 2004; 15(Suppl 1): S55-S57.
88. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007; 292: F905-F911.
89. Johnson TS, Griffin M, Thomas GL et al. The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 1997; 99: 2950-2960.
90. Johnson TS, Abo-Zenah H, Skill JN et al. Tissue transglutaminase: a mediator and predictor of chronic allograft nephropathy? Transplantation 2004; 77: 1667-1675.
91. Johnson TS, El-Koraie AF, Skill NJ et al. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003; 14: 2052-2062.
92. Skill NJ, Johnson TS, Coutts IG et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem 2004; 279: 47754-47762.